(NASDAQ:ANNX), BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference […]

(NASDAQ:LFVN), SALT LAKE CITY, Jan. 07, 2026 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the addition of Mike Edwards as Chief Technology Officer. Edwards brings more than 25 years of experience as an accomplished senior

(NasdaqGM:KRUS), IRVINE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Kura Sushi USA, Inc. (“Kura Sushi” or the “Company”) (NASDAQ: KRUS), a technology-enabled Japanese restaurant concept, today announced financial results for the fiscal first quarter ended November 30, 2025. Fiscal First Quarter 2026 Highlights Total sales were $73.5 million, compared to $64.5 million in the first

(NasdaqGM:TTRX), LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) — Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhurst brings more than 30 years of global leadership

(PinkSheets:BSEM),(Pinksheets:BSEM), Decision ensures continued patient access to VENDAJE(R) and VENDAJE AC(R) POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today commented on the withdrawal of all seven of the Centers for

(NASDAQ:TERN), CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of

(NASDAQ:SMTI), Contract awarded for products that bring improvement to the healthcare industry FORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in

(NASDAQ:IMSR),(NASDAQ:IMSRW), CHARLOTTE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) — Terrestrial Energy Inc. (NASDAQ: IMSR) (“Terrestrial Energy” or “the Company”), a developer of small modular nuclear power plants using its Generation IV reactor technology, announced today that it will participate in the 28th Annual Needham Growth Conference on Tuesday, January 13, 2026, in New York, NY.

(NasdaqGM:TWLVU), New York, NY, Jan. 07, 2026 (GLOBE NEWSWIRE) — Twelve Seas Investment Company III (Nasdaq: TWLVU) (the “Company“) announced today that, commencing January 9, 2026, holders of the units sold in the Company's initial public offering may elect to separately trade the Company's Class A ordinary shares and rights included in the units. The

(NYSE:STZ),(NYSE:STZ-B), ROCHESTER, N.Y., Jan. 07, 2026 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, reported today its third quarter fiscal 2026 financial results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Chief Financial Officer, Garth Hankinson,